SCHEMBL7590667

SCHEMBL7590667

CC(=O)OC[PH](c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MAPK1 P28482 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SLC18A3 Q16572 2/20 0.36
GAA P10253 1/20 0.36
TSHR P16473 3/20 0.36
ELANE P08246 1/20 0.36
LMNA P02545 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ESR1 P03372 1/20 0.36
ITGB3 P05106 1/20 0.36
ITGA2B P08514 1/20 0.36
HMGB1 P09429 1/20 0.36
GGT1 P19440 1/20 0.36
PTGS1 P23219 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27649890 0.81 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2MAPTHPGDNPC1
Ethyl Acetate SCHEMBL1651993 0.79 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2MAPTNPC1GAA
SCHEMBL64221 0.78 ALDH1A1 (0.50) ALDH1A1MAPK1L3MBTL1SLC18A3TSHR
SCHEMBL887521 0.77 ALDH1A1 (0.49) ALDH1A1MAPK1L3MBTL1SLC18A3TSHR
Bromide SCHEMBL29016324 0.77 ALDH1A1 (0.49) ALDH1A1MAPK1L3MBTL1SLC18A3TSHR
SCHEMBL18295996 0.75 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2MAPTHPGDNPC1
SCHEMBL5076288 0.75 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2MAPTHPGDNPC1
SCHEMBL3794162 0.75 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTMAPK1L3MBTL1
SCHEMBL5076286 0.75 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2MAPTHPGDNPC1
Acetic Acid Methyl Ester SCHEMBL1399932 0.74 ALDH1A1 (0.41) ALDH1A1MAPTNPC1GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103237795-A Substituted oxadiazole compounds and their use as S1P1Use of agonists BRISTOL MYERS SQUIBB CO 2013-08-07 CN disclosed
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives OSI PHARMACEUTICALS, INC. 2002-06-27 US disclosed
US-6348032-B1 POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. CELL PATHWAYS, INC. 2002-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives MKI67, CCNI, TMBIM6 ALDH1A1 487/4885SMN1; SMN2 4367/4885MAPT 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.